Market Closed -
Nasdaq
04:00:00 2024-06-06 pm EDT
|
5-day change
|
1st Jan Change
|
3.1
USD
|
+0.65%
|
|
+1.31%
|
-3.73%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
198.4
|
146.5
|
218.6
|
131.1
|
227.6
|
219.9
|
-
|
-
|
Enterprise Value (EV)
1 |
198.4
|
146.5
|
218.6
|
131.1
|
227.6
|
219.9
|
219.9
|
219.9
|
P/E ratio
|
-2.69
x
|
-1.66
x
|
1.82
x
|
-2.42
x
|
-4.35
x
|
-3.6
x
|
-11
x
|
-4.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
11.6
x
|
1.05
x
|
87.2
x
|
581
x
|
106
x
|
4.06
x
|
8.35
x
|
EV / Revenue
|
-
|
11.6
x
|
1.05
x
|
87.2
x
|
581
x
|
106
x
|
4.06
x
|
8.35
x
|
EV / EBITDA
|
-
|
-
|
1.76
x
|
-2.38
x
|
-3.95
x
|
-3.11
x
|
-11.5
x
|
-3.39
x
|
EV / FCF
|
-3.88
x
|
-
|
-
|
-
|
-
|
-2.74
x
|
-2.96
x
|
-2.67
x
|
FCF Yield
|
-25.8%
|
-
|
-
|
-
|
-
|
-36.5%
|
-33.8%
|
-37.5%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
47,816
|
63,435
|
68,092
|
70,467
|
70,681
|
70,945
|
-
|
-
|
Reference price
2 |
4.150
|
2.310
|
3.210
|
1.860
|
3.220
|
3.100
|
3.100
|
3.100
|
Announcement Date
|
3/11/20
|
3/15/21
|
3/15/22
|
3/13/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
12.62
|
208.4
|
1.503
|
0.3917
|
2.071
|
54.11
|
26.35
|
EBITDA
1 |
-
|
-
|
124.4
|
-55.04
|
-57.68
|
-70.63
|
-19.15
|
-64.79
|
EBIT
1 |
-61.41
|
-81.43
|
149.2
|
-55.55
|
-59.28
|
-69.68
|
-18.79
|
-54.28
|
Operating Margin
|
-
|
-645.4%
|
71.58%
|
-3,696.43%
|
-15,134.4%
|
-3,364.02%
|
-34.74%
|
-205.99%
|
Earnings before Tax (EBT)
1 |
-60.46
|
-81.04
|
124.2
|
-54.17
|
-52.34
|
-62.68
|
-15.47
|
-51.31
|
Net income
1 |
-60.46
|
-81.04
|
122.8
|
-54.17
|
-52.34
|
-61.97
|
-22.95
|
-57.91
|
Net margin
|
-
|
-642.26%
|
58.95%
|
-3,604.66%
|
-13,362%
|
-2,991.76%
|
-42.41%
|
-219.75%
|
EPS
2 |
-1.540
|
-1.390
|
1.760
|
-0.7700
|
-0.7400
|
-0.8607
|
-0.2831
|
-0.6732
|
Free Cash Flow
1 |
-51.15
|
-
|
-
|
-
|
-
|
-80.32
|
-74.35
|
-82.45
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-3,877.76%
|
-137.41%
|
-312.89%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/15/21
|
3/15/22
|
3/13/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
1.445
|
-
|
0.0111
|
0.0463
|
0.0662
|
0.075
|
0.109
|
0.1416
|
0.148
|
0.0406
|
0.0388
|
2.025
|
0.0667
|
0.1
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-17.79
|
-17.28
|
-17.7
|
-17.87
|
-18.05
|
-
|
-
|
EBIT
1 |
-11.65
|
-14.29
|
-14.3
|
-12.8
|
-12.17
|
-14.89
|
-14.17
|
-12.03
|
-18.19
|
-17.42
|
-17.94
|
-18.61
|
-16.75
|
-19.01
|
-19.27
|
Operating Margin
|
-
|
-988.59%
|
-
|
-115,350.09%
|
-26,302.29%
|
-22,509.52%
|
-18,895.97%
|
-11,038.66%
|
-12,848.51%
|
-11,768.24%
|
-44,157.93%
|
-48,021.03%
|
-827.02%
|
-28,509.07%
|
-19,274%
|
Earnings before Tax (EBT)
1 |
-26.35
|
-16.06
|
-14.59
|
-11.97
|
-11.5
|
-13.36
|
-12.41
|
-11.25
|
-15.32
|
-11.69
|
-16.28
|
-16.94
|
-15.35
|
-17.01
|
-17.39
|
Net income
1 |
-26
|
-16.11
|
-14.59
|
-11.97
|
-11.5
|
-13.36
|
-12.41
|
-11.25
|
-15.32
|
-11.69
|
-16.28
|
-16.94
|
-15.35
|
-17.01
|
-17.39
|
Net margin
|
-
|
-1,114.46%
|
-
|
-107,817.75%
|
-24,858.64%
|
-20,187.74%
|
-16,544.44%
|
-10,326.14%
|
-10,823.71%
|
-7,901.35%
|
-40,066.67%
|
-43,726.48%
|
-758.07%
|
-25,507.72%
|
-17,392%
|
EPS
2 |
-0.3800
|
-0.2300
|
-0.2100
|
-0.1700
|
-0.1600
|
-0.1900
|
-0.1800
|
-0.1600
|
-0.2200
|
-0.1700
|
-0.2288
|
-0.2329
|
-0.2107
|
-0.2325
|
-0.2275
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/15/22
|
5/10/22
|
8/9/22
|
11/8/22
|
3/13/23
|
5/5/23
|
8/4/23
|
11/3/23
|
3/8/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-51.1
|
-
|
-
|
-
|
-
|
-80.3
|
-74.4
|
-82.4
|
ROE (net income / shareholders' equity)
|
-
|
-
|
110%
|
-34.7%
|
-47.6%
|
-110%
|
-80.4%
|
-143%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.06
|
-
|
-
|
-
|
0.14
|
0.02
|
0.41
|
0.59
|
Capex / Sales
|
-
|
-
|
-
|
-
|
35.09%
|
1.01%
|
0.76%
|
2.23%
|
Announcement Date
|
3/11/20
|
3/15/21
|
3/15/22
|
3/13/23
|
3/8/24
|
-
|
-
|
-
|
Average target price
7.562
USD Spread / Average Target +143.95% Consensus |
1st Jan change
|
Capi.
|
---|
| -3.73% | 220M | | +19.33% | 125B | | +13.95% | 108B | | -3.53% | 24.57B | | +3.32% | 22.82B | | -10.44% | 18.19B | | -41.48% | 16.54B | | -12.62% | 16.5B | | +0.99% | 13.39B | | +21.79% | 11.1B |
Bio Therapeutic Drugs
|